Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
Frequently Asked Questions
What is Market Cap of Celgene Corp.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Celgene Corp. market cap is N/A.
What is the 52-week high for Celgene Corp.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Celgene Corp. 52 week high is N/A as of September 12, 2025.
What is the 52-week low for Celgene Corp.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Celgene Corp. 52 week low is N/A as of September 12, 2025.
What was Celgene Corp. stock price yesterday?
Celgene Corp. stock price yesterday was $108.24.
What is the PE ratio of Celgene Corp.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Celgene Corp.’s P/E ratio is None.
What is the Price-to-Book ratio of Celgene Corp.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Celgene Corp. P/B ratio is None.
What is Celgene Corp.'s EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Celgene Corp.'s EBITDA is 9.33.
What is the 50-day moving average of Celgene Corp.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Celgene Corp. 50-day moving average is N/A.
